The EDC is live today — see what ships now
Trialion
All studies
NCT07519772From ClinicalTrials.govRecruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse

At a glance

Phase
Phase 1
Study type
Interventional
Sponsor
Merck Sharp & Dohme LLC
Enrolment target
280
Started
3 May 2026
Main results due
1 July 2030
Study sites
41
Registry updated
25 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.
* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.
* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).
* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.
* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.
* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.
* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.
* Has radiographically measurable disease per Lugano Response Criteria.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has received a solid organ transplant.
* Had or has clinically relevant central nervous system (CNS) diseases.
* Has a history of serious cardiovascular or cerebrovascular diseases.
* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.
* Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Has received a live or live-attenuated vaccine within 30 days of randomization.
* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.
* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.
* Has known active CNS lymphoma or involvement.
* Has active autoimmune disease that required systemic treatment in the past 2 years.
* Has active infection requiring systemic therapy.
* Has a history of severe bleeding disorders.
* Has not recovered from major surgery or has ongoing surgical complications.
* Has diagnosis of primary mediastinal B-cell lymphoma.

What this study is about

In the sponsor’s own words, from the registry.

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.

In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.

The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.

Study sites(41)

  • Colorado Blood Cancer Institute ( Site 7000)

    Denver, Colorado, United States

    Recruiting

  • SCRI Oncology Partners ( Site 0100)

    Nashville, Tennessee, United States

    Recruiting

  • Instituto Alexander Fleming ( Site 1404)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

    Recruiting

  • Hospital Universitario Austral ( Site 1402)

    Pilar, Buenos Aires, Argentina

    Recruiting

  • Sanatorio Nuestra Senora del Rosario ( Site 1403)

    Rosario, Santa Fe Province, Argentina

    Recruiting

  • Hospital Aleman ( Site 1400)

    CABA, Argentina

    Recruiting

  • Townsville University Hospital ( Site 0204)

    Townsville, Queensland, Australia

    Recruiting

  • Box Hill Hospital ( Site 0202)

    Box Hill, Victoria, Australia

    Recruiting

  • Princess Margaret Cancer Centre ( Site 0301)

    Toronto, Ontario, Canada

    Recruiting

  • Clínica Alemana de Santiago ( Site 1608)

    Santiago, Region M. de Santiago, Chile

    Recruiting

  • Beijing Cancer hospital ( Site 1701)

    Beijing, Beijing Municipality, China

    Recruiting

  • Sun Yat-Sen University Cancer Center ( Site 1712)

    Guangzhou, Guangdong, China

    Recruiting

  • Fudan University Shanghai Cancer Center ( Site 1711)

    Shanghai, Shanghai Municipality, China

    Recruiting

  • UKGM Gießen/Marburg ( Site 0505)

    Giessen, Hesse, Germany

    Recruiting

  • Carmel Hospital ( Site 0602)

    Haifa, Israel

    Recruiting

  • Shaare Zedek Medical Center ( Site 0603)

    Jerusalem, Israel

    Recruiting

  • Haddasah Medical Center ( Site 0600)

    Jerusalem, Israel

    Recruiting

  • Sheba Medical Center ( Site 0601)

    Ramat Gan, Israel

    Recruiting

  • Sourasky Medical Center. ( Site 0604)

    Tel Aviv, Israel

    Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Ematologia Oncologica ( Site 0700)

    Campania, Napoli, Italy

    Recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo ( Site 0701)

    Candiolo, Piedmont, Italy

    Recruiting

  • Istituto Europeo di Oncologia IRCCS ( Site 0702)

    Milan, Italy

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0705)

    Roma, Italy

    Recruiting

  • Pratia MCM Krakow ( Site 0903)

    Krakow, Lesser Poland Voivodeship, Poland

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)

    Warsaw, Masovian Voivodeship, Poland

    Recruiting

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0901)

    Gliwice, Silesian Voivodeship, Poland

    Recruiting

  • Pratia Onkologia Katowice ( Site 0902)

    Katowice, Silesian Voivodeship, Poland

    Recruiting

  • Seoul National University Hospital ( Site 0800)

    Seoul, South Korea

    Recruiting

  • The Catholic University of Korea, Yeouido St. Mary's Hospital ( Site 0801)

    Seoul, South Korea

    Recruiting

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 1103)

    Badalona, Barcelona, Spain

    Recruiting

  • Hospital Virgen de la Victoria ( Site 1104)

    Málaga, Malaga, Spain

    Recruiting

  • Hospital Universitari Vall de Hebron ( Site 1102)

    Barcelona, Spain

    Recruiting

  • Hospital Universitario Gregorio Maranon ( Site 1101)

    Madrid, Spain

    Recruiting

  • Hospital Universitario 12 de Octubre ( Site 1105)

    Madrid, Spain

    Recruiting

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1000)

    Ankara, Turkey (Türkiye)

    Recruiting

  • Antalya Egitim ve Arastirma Hastanesi ( Site 1003)

    Antalya, Turkey (Türkiye)

    Recruiting

  • Koç Üniversitesi Hastanesi ( Site 1001)

    Istanbul, Turkey (Türkiye)

    Recruiting

  • Medipol Mega Universite Hastanesi ( Site 1002)

    Istanbul, Turkey (Türkiye)

    Recruiting

  • Samsun Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi ( Site 1005)

    Samsun, Turkey (Türkiye)

    Recruiting

  • Derriford Hospital ( Site 1304)

    Plymouth, Devon, United Kingdom

    Recruiting

  • The Christie NHS Foundation Trust ( Site 1300)

    Manchester, United Kingdom

    Recruiting

Showing 41 of 41 sites. 41 of the 41 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07519772. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Trialion